Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.

Abstract

INTRODUCTION:

High-dose intravenous immunoglobulin (IVIg) is an evidence-based treatment for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Recently, subcutaneous immunoglobulin (SC-Ig) has received increasing attention.

METHODS:

We performed a meta-analysis of reports of efficacy and safety of SC-Ig versus IVIg for inflammatory demyelinating polyneuropathies.

RESULTS:

A total of 8 studies comprising 138 patients (50 with MMN and 88 with chronic CIDP) were included in the meta-analysis. There were no significant differences in muscle strength outcomes in MMN and CIDP with Sc-Ig (MMN: effect size [ES] = 0.65, 95% confidence interval [CI] = -0.31-1.61; CIDP: ES = 0.84, 95% CI = -0.01-1.69). Additionally SC-Ig had a 28% reduction in relative risk (RR) of moderate and/or systemic adverse effects (95% CI = 0.11-0.76).

CONCLUSIONS:

The efficacy of SC-Ig is similar to IVIg for CIDP and MMN and has a significant safety profile. Muscle Nerve 55: 802-809, 2017.

• Authors: Juan M Racosta, Luciano A Sposato, Kurt Kimpinski
• Journal: Muscle & nerve (Muscle Nerve) Vol. 55 Issue 6 Pg. 802-809 (06 2017) ISSN: 1097-4598 [Electronic] United States
• PMID: 27649063 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: © 2016 Wiley Periodicals, Inc.

Chemical References

• Immunoglobulins
• Immunoglobulins, Intravenous

Topics

• Administration, Cutaneous
• Databases, Bibliographic (statistics & numerical data)
• Female
• Humans
• Immunoglobulins (administration & dosage)
• Immunoglobulins, Intravenous (therapeutic use)
• Male
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy)